Skip to main
TVRD

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 20%
Sell 20%
Strong Sell 0%

Bulls say

Tvardi Therapeutics is a promising company with a positive outlook due to the potential expansion of their drug TTI-109 into multiple disease indications, along with the positive results of TTI-101 in Phase 1 trials for HCC and IPF. The company's focus on targeting STAT3, along with potential growth opportunities through partnerships and indication expansion, make it a strong candidate for investment. However, there are potential risks with regulatory approval and competition in the commercial market.

Bears say

Tvardi Therapeutics is a biopharmaceutical company that is focused on developing novel, oral, small molecule therapies for diseases with unmet need. While the company's pipeline includes two oral, small molecule STAT3 inhibitors, their lead program TTI-109 is still in early clinical trials and may face challenges in proving its efficacy. Additionally, the company has faced a clinical setback in their Phase 2 trial for idiopathic pulmonary fibrosis, raising concerns about their ability to successfully develop their drugs. Considering the challenges and uncertainties surrounding Tvardi's pipeline and clinical development, the financial analyst has a negative outlook on the company's stock.

TVRD has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cara Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 5 analysts, TVRD has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cara Therapeutics Inc (TVRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.